Description

GMAB’s $5B Power Play: Is Merus The Missing Piece In Its Cancer War Chest?

In the first half of 2025, Genmab showcased notable achievements and developments in its financial and operational performance. On the positive side, the company reported a 19% increase in total revenue, largely driven by increased recurring revenues from products like EPKINLY and Tivdak. Such growth demonstrates Genmab’s capacity to capitalize on its commercialized products, maintaining strong momentum in the market. Furthermore, the company’s operating profit grew by 56%, reflecting efficient management and strategic focus on advancing late-stage pipeline projects.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!